

Biodegradable Nanoparticles Composed Entirely of Safe Materials that Rapidly Penetrate Human Mucus**

Ming Yang, Samuel K. Lai, Ying-Ying Wang, Weixi Zhong, Christina Happe, Michael Zhang, Jie Fu, and Justin Hanes*

Mucus is a highly viscoelastic and adhesive substance that protects against infection and injury at nearly all entry points to the body not covered by skin. However, mucus also traps potentially life-saving drugs and nucleic acids delivered by synthetic nanoparticles, including those composed of poly(lactic-co-glycolic acid) (PLGA) and poly(ϵ -caprolactone) (PCL), two FDA-approved polymers commonly used in drug-delivery applications.^[1] Trapped particles, with diffusivities in mucus several-thousand-fold lower than in water, do not efficiently reach the deeper mucus layers that are cleared much more slowly, or the underlying epithelium, and are thus eliminated by mucus clearance mechanisms (on the order of seconds to a few hours depending on anatomical site^[2]). For sustained or targeted drug delivery to mucosal surfaces, nanoparticles must quickly penetrate mucus gels, a long-standing challenge in drug delivery.^[2c]

We recently demonstrated that covalently coating particles with a high density of low-molecular-weight (low MW)

poly(ethylene glycol) (PEG), a hydrophilic and uncharged polymer widely used in pharmaceuticals, can reduce particle affinity to mucus constituents.^[3] Densely coated particles were able to rapidly penetrate fresh, undiluted human mucus, with speeds only a few-fold lower than in water, by diffusing within the low-viscosity interstitial fluid between mucin fibers without experiencing the bulk viscosity of mucus.^[4] However, current methods of producing mucus-penetrating particles (MPPs) require covalent conjugation of PEG to polymers or pre-fabricated particles,^[3] resulting in new chemical entities (NCEs), which are subject to a lengthy and expensive FDA regulatory process. We sought to develop a simple non-covalent coating process to produce MPPs composed entirely of generally recognized as safe (GRAS) materials. Uncharged amphiphilic GRAS materials, such as triblock copolymers of poly(ethylene glycol)-poly(propylene oxide)-poly(ethylene glycol) (PEG-PPO-PEG; known as Pluronics), may coat hydrophobic particle surfaces by adsorption through the hydrophobic PPO segments, leaving a dense brush of uncharged, hydrophilic PEG segments protruding from the particle surface.^[5] Here, we show that a number of Pluronics molecules, containing PPO segments with MW $\geq$ 3 kDa, can effectively coat PLGA, PCL, and latex nanoparticles, thereby enabling the formulation of MPPs composed entirely of GRAS materials, with no NCEs generated. Synthetic MPPs composed entirely of GRAS materials will likely facilitate rapid translation of nanomaterials-based products into humans for the treatment of numerous diseases and conditions that affect mucosal tissues.

Pluronics of different MW and PPO/PEG ratios have been adopted for various biomedical applications.^[6] We first sought to identify which Pluronics may coat normally mucoadhesive polymeric nanoparticles sufficiently to transform them into MPPs. As a proof-of-concept, we formulated fluorescently labeled PLGA nanoparticles, and incubated separate batches with Pluronic P65, F38, P103, P105, F68, or F127 (listed in order of increasing MW) followed by purification. We then observed nanoparticle transport dynamics in freshly obtained, undiluted human cervicovaginal mucus (CVM). Uncoated PLGA nanoparticles were extensively immobilized in CVM (Figure 1a). Three of the Pluronics (F38, P65, and F68) tested did not enhance the transport of PLGA particles, as evident by the highly constrained, non-Brownian time-lapse traces of the particles in mucus (Figure 1b). In contrast, coating PLGA particles with P103, P105, or F127 allowed them to readily penetrate CVM, as evident by their diffusive, Brownian trajectories that covered large distances over the course of 20 s movies (Figure 1c). The effectiveness of the Pluronic coatings was critically dependent on the MW of the PPO

[*] Prof. Dr. J. Hanes

Departments of Ophthalmology, Biomedical Engineering, Chemical & Biomolecular Engineering and Oncology
Center for Cancer Nanotechnology Excellence
Institute for NanoBioTechnology and Center for Nanomedicine
Johns Hopkins University School of Medicine
400 North Broadway, Baltimore, MD 21287 (USA)
Fax: (+1) 410-614-6509
E-mail: hanes@jhu.edu
Homepage: <http://www.jhu.edu/haneslab/>

M. Yang,^[†] Y.-Y. Wang, W. Zhong

Department of Biomedical Engineering
Johns Hopkins University, Baltimore (USA)

Dr. S. K. Lai,^[*] C. Happe, M. Zhang
Department of Chemical & Biomolecular Engineering
Johns Hopkins University, Baltimore (USA)

Dr. J. Fu
Department of Ophthalmology
Johns Hopkins University, Baltimore (USA)

[#] Current address: Eshelman School of Pharmacy
University of North Carolina at Chapel Hill, Chapel Hill (USA)

[†] These authors contributed equally to this work.

[**] We thank the Integrated Imaging Center at Johns Hopkins University. This work was supported by the NIH (R21AI079740, R01A140746, R21L089816 and U54A151838), a Croucher Foundation Fellowship to S.K.L., and a National Science Foundation Graduate Research Fellowship to Y.-Y.W. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the National Cancer Institute.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201006849>.




Figure 1. Transport behavior of uncoated and Pluronic-coated PLGA particles in fresh human CVM. Representative trajectories of a) uncoated PLGA particles, b) particles coated with low PPO MW Pluronic (F68, F38, or P65), and c) particles coated with high PPO MW Pluronic (F127, P103, or P105). d) Phase diagram correlating muco-inert versus mucoadhesive particle behavior to Pluronic PPO and PEG segment MW. Filled symbols indicate MPP formulations, while open symbols indicate mucoadhesive formulations.

segment (Figure 1 d), perhaps because hydrophobic adhesive interactions between short PPO segments and PLGA are inadequate to anchor a dense brush of Pluronic molecules (and consequently PEG) onto the particle surface. Indeed, P103, P105, and F127, all with PPO MW ≥ 3 kDa, produced coated particles with a ζ -potential between -8 mV and 0 mV (Figure 2 a), compared to -50 mV for uncoated particles; we previously found that PEG coatings that effectively shield latex particles from mucoadhesion exhibited a near-neutral particle ζ -potential (within -10 mV of neutral).^[3b] In contrast, PLGA nanoparticles incubated in F38, P65, and F68, each with PPO MW < 3 kDa, exhibited surface charges between -30 and -35 mV, indicating partial, but inadequate, surface PEG coverage. There was no correlation between Pluronic coating density and either the MW of the PEG segments or total Pluronic MW (Figure 2 b and c). It is possible that the Pluronic coating may desorb from particles over time. However, we have observed that the surface charges for P103-, P105-, and F127-coated particles remain neutral at 4°C in buffer 24 h after particle synthesis, suggesting the coatings are stable at least over that duration (data not shown).




Figure 2. Muco-inert versus mucoadhesive behavior of PLGA particles coated with various Pluronics (F38, P65, P103, P105, F68, and F127) in fresh human CVM. a–c) Correlation between the ζ -potential of Pluronic-coated PLGA particles and the MW of the a) PPO segment, b) PEG segment, or c) entire Pluronic molecule. “Water” indicates the ζ -potential of uncoated PLGA particles made in water. Filled symbols indicate MPP formulations, while open symbols indicate mucoadhesive formulations. r represents the correlation coefficient.

Pluronic F127 is one of the most commonly used Pluronics for pharmaceutical applications;^[6b,d,7] we thus focused subsequent investigations on F127-coated particles. To quantify the speeds of F127-coated PLGA nanoparticles (PLGA/F127 NPs) in mucus, we analyzed the motions of PLGA/F127 NPs using multiple particle tracking, a technique that allows quantitative measurements of hundreds of individual particles.^[2c,8] The time-scale-dependent ensemble mean-squared

displacement ($\langle \text{MSD} \rangle$) of PLGA/F127 NPs was 280-fold higher than that for uncoated PLGA nanoparticles (PLGA NPs) at a time scale of 1 s (Figure 3a). Few, if any, PLGA/F127 NPs were trapped in mucus compared to PLGA NPs (Figure 3b). Importantly, PLGA/F127 NPs were slowed only about 10-fold in CVM compared to their theoretical speeds in water, whereas PLGA NPs were slowed down about 4000-fold (Table S1 in the Supporting Information). The similar speeds of PLGA/F127 NPs and nanoparticles with covalently conjugated low MW PEG^[3] suggest that noncovalent coating with Pluronic F127, as well as other Pluronics with PPO MW ≥ 3 kDa, shields adhesive particle surfaces as efficiently as does a covalent PEG coating. We also tested particles composed of other mucoadhesive polymers, including the widely used PCL polymer and a generic hydrophobic polymer, polystyrene (PS; also known as latex). For both, we observed extensive immobilization for uncoated particles

and rapid mucus penetration for F127-coated particles, with effective diffusivities similar to those measured for PLGA NPs and PLGA/F127 NPs, respectively (Figure S1). The majority of F127-coated nanoparticles (60–80%), regardless of the core material, are expected to penetrate physiologically thick mucus layers within 30 min, whereas $< 1\%$ of uncoated particles will do so over the same duration (Figures 3c, S1g, and S1h).

Our findings highlight numerous potential advantages of using Pluronic-coated particles for drug-delivery applications. First, Pluronics have an extensive safety profile and have been used since the 1950s^[6a] in many commercially available products, including drug-delivery devices.^[9] Combining Pluronics with other GRAS materials may, therefore, produce mucus-penetrating drug-delivery platforms that are likely to be safe in humans, and also greatly simplify manufacturing while reducing the time and costs for clinical development. Second, since this method involves only a short incubation of prefabricated particles with Pluronics, the formulation process of the drug-loaded particle core remains unchanged. The simplicity of the coating process may accelerate economical and scalable translational development of the MPP technology. Third, tailored release profiles and high encapsulation efficiencies may be achieved for a wide array of cargo therapeutics simply by selecting an appropriate GRAS material, with optimal degradation kinetics and polymer–drug affinity, for the particle core.^[10] Using an optimal core material may also help minimize the potential buildup of unwanted polymers in the body, as can occur with repeated administration of carriers that release drug quickly but are composed of slowly degrading polymers.^[11] Fourth, we expect Pluronics coatings to facilitate rapid particle penetration at other mucosal surfaces, since human CVM possesses biochemical content and rheological properties similar to those of mucus fluids derived from the eyes, nose, lungs, gastrointestinal tract, and more.^[3a] Indeed, we have found that a Pluronic F127 coating markedly improves the transport of polymeric particles in both sputum expectorated by cystic fibrosis patients as well as mucus collected by surgery from the nasal cavity of patients with chronic sinusitis (unpublished observations).

We show here that otherwise mucoadhesive polymeric particles can be sufficiently coated with specific Pluronics to allow rapid nanoparticle penetration of human mucus secretions without introducing any NCE. Enhanced mucus penetration is expected to facilitate prolonged retention and more uniform distribution of drug carriers at mucosal surfaces, leading to improved pharmacokinetics and therapeutic efficacy.^[2c] While Pluronics were investigated here, we expect other molecules may similarly reduce particle mucoadhesion by forming noncovalent coatings that block adhesive interactions. The continual development of alternative, noncovalent coatings for biodegradable polymer nanoparticles will further expand the diversity of mucosal delivery systems for the treatment of mucosal diseases, including infections, cancer, and inflammation in the eyes, sinuses, female reproductive tract, respiratory tract, and gastrointestinal tract.




Figure 3. Transport of uncoated and F127-coated PLGA particles in human CVM. a) Ensemble-averaged geometric mean-square displacements ($\langle \text{MSD} \rangle$) as a function of time scale; * denotes statistically significant difference across all time scales ($p < 0.05$). b) Distributions of the logarithms of individual particle effective diffusivities (D_{eff}) at a time scale of 1 s. c) Estimated fraction of particles predicted to be capable of penetrating a 30 μm thick mucus layer over time.

Experimental Section

The general experimental methods were as follows (details are available in Supporting Information): Pluronic-coated biodegradable nanoparticles were synthesized in water, followed by collection and simple incubation in 1 % w/v Pluronic solution, and were purified by size exclusion chromatography. Particles were characterized for size and surface charge. The displacements of uncoated and Pluronic-coated particles were tracked in fresh, undiluted human CVM using multiple particle tracking.^[3,12]

Received: November 1, 2010

Published online: February 18, 2011

Keywords: drug delivery · GRAS (generally recognized as safe) · mucus-penetrating particles · nanotechnology · Pluronics

-
- [1] a) A. S. Hoffman, *J. Controlled Release* **2008**, *132*, 153; b) A. Kumari, S. K. Yadav, S. C. Yadav, *Colloids Surf. B* **2010**, *75*, 1; c) F. Mohamed, C. F. van der Walle, *J. Pharm. Sci.* **2008**, *97*, 71; d) D. Putnam, *Nat. Mater.* **2006**, *5*, 439.
- [2] a) R. A. Cone, *Adv. Drug Delivery Rev.* **2009**, *61*, 75; b) M. R. Knowles, R. C. Boucher, *J. Clin. Invest.* **2002**, *109*, 571; c) S. K. Lai, Y. Y. Wang, J. Hanes, *Adv. Drug Delivery Rev.* **2009**, *61*, 158.
- [3] a) S. K. Lai, D. E. O'Hanlon, S. Harrold, S. T. Man, Y. Y. Wang, R. Cone, J. Hanes, *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 1482; b) Y. Y. Wang, S. K. Lai, J. S. Suk, A. Pace, R. Cone, J. Hanes, *Angew. Chem.* **2008**, *120*, 9872; *Angew. Chem. Int. Ed.* **2008**, *47*, 9726.
- [4] a) S. K. Lai, Y. Y. Wang, K. Hida, R. Cone, J. Hanes, *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 598; b) S. K. Lai, Y. Y. Wang, D. Wirtz, J. Hanes, *Adv. Drug Delivery Rev.* **2009**, *61*, 86.
- [5] L. Illum, S. S. Davis, *FEBS Lett.* **1984**, *167*, 79.
- [6] a) R. M. Emanuele, *Expert Opin. Invest. Drugs* **1998**, *7*, 1193; b) E. V. Batrakova, A. V. Kabanov, *J. Controlled Release* **2008**, *130*, 98; c) G. T. Rodeheaver, L. Kurtz, B. J. Kircher, R. F. Edlich, *Ann. Emerg. Med.* **1980**, *9*, 572; d) J. J. Escobar-Chavez, M. Lopez-Cervantes, A. Naik, Y. N. Kalia, D. Quintanar-Guerrero, A. Ganem-Quintanar, *J. Pharm. Pharm. Sci.* **2006**, *9*, 339.
- [7] G. Dumortier, J. L. Grossiord, F. Agnely, J. C. Chaumeil, *Pharm. Res.* **2006**, *23*, 2709.
- [8] J. Suh, M. Dawson, J. Hanes, *Adv. Drug Delivery Rev.* **2005**, *57*, 63.
- [9] a) D. Donaldson, S. C. Gelskey, R. G. Landry, D. C. Matthews, H. S. Sandhu, *J. Clin. Periodontol.* **2003**, *30*, 171; b) J. B. Lo, L. E. Appel, S. M. Herbig, S. B. McCray, A. G. Thombre, *Drug Dev. Ind. Pharm.* **2009**, *35*, 1522; c) C. H. Pui, *Expert Opin. Pharmacother.* **2002**, *3*, 433.
- [10] a) J. Tamada, R. Langer, *J. Biomater. Sci. Polym. Ed.* **1992**, *3*, 315; b) Y. Yeo, K. Park, *Arch. Pharmacol. Res.* **2004**, *27*, 1.
- [11] J. Fu, J. Fiegel, E. Krauland, J. Hanes, *Biomaterials* **2002**, *23*, 4425.
- [12] M. Dawson, D. Wirtz, J. Hanes, *J. Biol. Chem.* **2003**, *278*, 50393.
-